1345 related articles for article (PubMed ID: 10400039)
1. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
3. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
[TBL] [Abstract][Full Text] [Related]
4. Complete axillary conversion after neoadjuvant chemotherapy in locally advanced breast cancer: a step towards conserving axilla?
Arimappamagan A; Kadambari D; Srinivasan K; Krishnan R; Elangovan S; Reddy KS
Indian J Cancer; 2004; 41(1):13-7. PubMed ID: 15105574
[TBL] [Abstract][Full Text] [Related]
5. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
[TBL] [Abstract][Full Text] [Related]
6. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
[TBL] [Abstract][Full Text] [Related]
7. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Vlastos G; Mirza NQ; Lenert JT; Hunt KK; Ames FC; Feig BW; Ross MI; Buzdar AU; Singletary SE
Cancer; 2000 Mar; 88(6):1417-24. PubMed ID: 10717625
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
9. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE
J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586
[TBL] [Abstract][Full Text] [Related]
10. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
11. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
Dominici LS; Negron Gonzalez VM; Buzdar AU; Lucci A; Mittendorf EA; Le-Petross HT; Babiera GV; Meric-Bernstam F; Hunt KK; Kuerer HM
Cancer; 2010 Jun; 116(12):2884-9. PubMed ID: 20564395
[TBL] [Abstract][Full Text] [Related]
12. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Breslin TM; Cohen L; Sahin A; Fleming JB; Kuerer HM; Newman LA; Delpassand ES; House R; Ames FC; Feig BW; Ross MI; Singletary SE; Buzdar AU; Hortobagyi GN; Hunt KK
J Clin Oncol; 2000 Oct; 18(20):3480-6. PubMed ID: 11032588
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
Sakakibara M; Nagashima T; Kadowaki M; Onai Y; Fujimori T; Yokomizo J; Suzuki H; Fushimi K; Nakatani Y; Miyazaki M
Ann Surg Oncol; 2009 Sep; 16(9):2470-8. PubMed ID: 19588201
[TBL] [Abstract][Full Text] [Related]
14. [Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
Jiménez-Ballvé A; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Salsidua-Arroyo O; Román-Santamaría JM; Pelayo Alarcón A; Fuentes Ferrer ME; Carreras-Delgado JL
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):230-5. PubMed ID: 25743035
[TBL] [Abstract][Full Text] [Related]
15. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
[TBL] [Abstract][Full Text] [Related]
16. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
[TBL] [Abstract][Full Text] [Related]
17. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.
Newman EA; Sabel MS; Nees AV; Schott A; Diehl KM; Cimmino VM; Chang AE; Kleer C; Hayes DF; Newman LA
Ann Surg Oncol; 2007 Oct; 14(10):2946-52. PubMed ID: 17514407
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
20. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]